Browse > Article

Second allogeneic hematopoietic stem cell transplantation in children to overcome graft failure or relapse after initial transplant  

Kim, Dong-Yeon (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Kim, Do Kyun (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Kim, Soo Young (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Kim, Seok Joo (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Han, Dong Gyun (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Baek, Hee Jo (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Kook, Hoon (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Hwang, Tai-Ju (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hwasun Hospital, Blood & Marrow Transplantation Center)
Publication Information
Clinical and Experimental Pediatrics / v.49, no.12, 2006 , pp. 1329-1339 More about this Journal
Abstract
Purpose : Failure of hematopoietic stem cell transplantation(HSCT) may be encountered in practice because of either relapse of the malignancy or dysfunction of the graft. Second HSCT may be the only option for some patients whose initial HSCT failed. Methods : From May, 1991 to December, 2004, 115 HSCTs were performed at the Pediatric Blood & Marrow Transplantation Center, Chonnam National University. This study was a retrospective analysis of the medical records of 15 patients who received the second HSCT after initial graft. Results : Among eight patients with nonmalignant diseases, two patients underwent the second HSCT because of primary graft failure and five because of late graft rejection. The remaining Fanconi anemia patient was re-transplanted due to development of AML. Two patients died and one experienced primary graft failure, but is still alive. The Kaplan-Meier 5-year overall survival rate was 75 percent and the disease free survival rate was 62.5 percent in nonmalignant diseases. All malignant patients underwent second transplants because of relapses. Four died of relapse and one of treatment-related complications. The Kaplan-Meier 2-year overall and event free survival rate was 28.6 percent each in malignant diseases. Conclusion : Second HSCT for graft dysfunction of nonmalignant disease seems to be feasible and should be considered as a standard practice. The relapse of malignant diseases remains a big obstacle even after the second HSCT, although a small portion of patients might be salvaged. Further investigation of novel therapeutic strategies, as well an the understanding of the biology should be explored.
Keywords
Hematopoietic stem cell transplantation; Second transplantation; Graft failure; Relapse;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000;108:400-7   DOI   ScienceOn
2 Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992;9:269-75
3 Kishi K, Takahashi S, Gondo H, Shiobara S, Kanamaru A, Kato S, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997;19:461-6   DOI
4 Deeg HJ. Graft failure. In : Burt RK, Deeg HJ, Lothian ST, Santos GW editors: On Call in Bone Marrow Transplantation. New York, Chapman & Hill, 1996:306-16
5 Storb R, Doney KC, Thomas ED, Appelbaum F, Buckner CD, Clift RA, et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982;59:236-46
6 de Medeiros CR, Bitencourt MA, Medeiros BC, Ioshizumi L, Pasquini R. Second bone marrow transplantation for severe aplastic anemia: analysis of 34 cases. Bone Marrow Transplant 2001;28:941-4   DOI
7 Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, et al. Donor lymphocyte infusions(DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;19:927-32   DOI
8 Sanders JE, Buckner CD, Clift RA, Fefer A, McGuffin R, Storb R, et al. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplant 1988;3:11-9
9 Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia(a 26-year retrospective analysis). Blood 1998;92: 2742-9
10 Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1990;75: 555-62
11 Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50
12 Isoyama K, Ohnuma K, Ikuta K, Toyoda Y, Nakajima F, Yamada K, et al. Unrelated cord blood transplantation for second hemopoietic stem cell transplantation. Pediatr Int 2003;45:268-74   DOI   ScienceOn
13 Chiang KY, Weisdorf DJ, Davies SM, Enright H, Kersey JH, McGlave PB, et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996;17:39-42
14 Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962-71   DOI   ScienceOn
15 Davies SM, Weisdorf DJ, Haake RJ, Kersey JH, McGlave PB, Ramsay NK, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14:73-7
16 Wingard JR, Piantadosi S, Santos GW, Saral R, Vriesendorp HM, Yeager AM, et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol 1990;8:820-30   DOI
17 Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602   DOI   ScienceOn
18 Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44   DOI
19 Engelfriet CP, Reesink HW, Wagner JE, Kogler G, Rocha V, Wernet P, et al. International forum. Use of umbilical cord blood progenitor cells as an alternative for bone marrow transplantation. Vox Sang 2002;83:172-87   DOI   ScienceOn
20 Gibson FM, Scopes J, Daly S, Ball S, Gordon-Smith EC. Haemopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture. Br J Haematol 1995;91:551-61   DOI   ScienceOn
21 Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999;27:1477-86   DOI   ScienceOn
22 Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-85   DOI
23 Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001;19:3675-84   DOI
24 Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993;81:1404-7
25 Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997;19:709-19   DOI
26 Russell JA, Bowen T, Brown C, Luider J, Ruether JD, Stewart D, et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplant 1996;18:501-5
27 Sierra J, Terol MJ, Urbano-Ispizua A, Rovira M, Marin P, Carreras E, et al. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation. Exp Hematol 1994;22:566-72
28 Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101:4233-44   DOI   ScienceOn
29 Jaime-Perez JC, Ruiz-Arguelles GJ, Gomez-Almaguer D. Haematopoietic stem cell transplantation to treat aplastic anaemia. Expert Opin Biol Ther 2005;5:617-26   DOI   ScienceOn
30 McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994;13:233-7
31 Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991;79:567-74   DOI   ScienceOn
32 Nemunaitis J, Singer JW, Buckner CD, Durnam D, Epstein C, Hill R, et al. Use of recombinant human granulocytemacrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990;76:245-53
33 Hows J, Palmer S, Gordon-Smith EC. Cyclosporine and graft failure following bone marrow transplantation for severe aplastic anaemia. Br J Haematol 1985;60:611-7   DOI   ScienceOn
34 Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000;111: 292-302   DOI   ScienceOn
35 Arseniev L, Tischler HJ, Battmer K, Sudmeier I, Casper J, Link H. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSFmobilized peripheral blood progenitor cells of the marrow donor. Bone Marrow Transplant 1994;14:791-7
36 Wagner JE, Vogelsang GB, Zehnbauer BA, Griffin CA, Shah N, Santos GW. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 1992;9:205-9
37 Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graftversus- host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991;7:453-9
38 Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 1997;126:107-15   DOI   ScienceOn